Ser122
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser122  -  LRRC16 (human)

Site Information
RkIFPGLsPVRIMKK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4725409

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 8 , 9 , 10 , 11 )
Disease tissue studied:
breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , cervical cancer ( 10 ) , cervical adenocarcinoma ( 10 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 )
Relevant cell line - cell type - tissue:
breast ( 1 , 3 ) , H2077 (pulmonary) ( 6 ) , H322 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC366 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 6 ) , HeLa (cervical) ( 2 , 5 , 9 ) , HeLa S3 (cervical) ( 10 ) , HepG2 (hepatic) ( 11 ) , HOP62 (pulmonary) ( 6 ) , Jurkat (T lymphocyte) ( 8 ) , NCI-H1395 (pulmonary) ( 6 ) , NCI-H1568 (pulmonary) ( 6 ) , NCI-H2030 (pulmonary) ( 6 ) , NCI-H520 (squamous) ( 6 ) , NCI-H647 (pulmonary) ( 6 ) , PC9 (pulmonary) ( 6 )

Upstream Regulation
Treatments:
BI2536 ( 9 ) , MLN8054 ( 9 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

5

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

8

Guo A (2012) CST Curation Set: 13982; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

9

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

10

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

11

Possemato A (2009) CST Curation Set: 7313; Year: 2009; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info